Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05167409 · ClinicalTrials.gov registry record · Phase 2
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
A Phase 2 study of Microsatellite Stable Metastatic Colorectal Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT05167409 is a Phase 2 study of Microsatellite Stable Metastatic Colorectal Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 48 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT05167409, a Phase 2 study of Microsatellite Stable Metastatic Colorectal Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cetuximab
- DRUG Evorpacept (ALX148)
Study Locations (4)
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
New Jersey
- Rutgers Cancer insititute - New Brunswick
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05167409
The ClinicalTrials.gov registry entry for NCT05167409 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Microsatellite Stable Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05167409 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Colorado, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05167409 about?
NCT05167409 is a clinical study titled "A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer". This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
What is the current status of trial NCT05167409?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2022-07-28. Estimated completion is 2026-03-01.
What conditions does trial NCT05167409 study?
This clinical trial studies the following conditions: Microsatellite Stable Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT05167409?
The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), Evorpacept (ALX148) (DRUG).
Who is sponsoring clinical trial NCT05167409?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05167409 being conducted?
This trial has 4 study locations across Arizona, Colorado, New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.